Physician-scientist and cancer immunotherapy drug developer with over 15 years of leadership experience in clinical oncology research in academia/industry as well as leadership of basic science and translational research programs. Experienced as leader of a wide variety of organizational structures including research programs in government, highly-matrixed early and late-stage global clinical development teams in large pharma and biotech sectors, international scientific organizations, partnered joint development committees (US/ex-US) and various boards/committees.

Specialties: Immuno-Oncology, Oncology, Hematology, Drug Development (small molecules, biologics, vaccines, etc.), Tumor Biology/Tumor Immunology, Cancer Immunotherapy, PD-1, PD-L1, LAG-3, B7-H3, CTLA-4, KIR, CD137, Nivolumab, Ipilimumab, DART, Bispecifics, Margetuximab, Enoblituzumab, Fc-optimization, Clinical Research, Combination Therapy, Apoptosis.